NCT00002011已完成不适用
The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Therakos
- 试验地点
- 1
研究概览
简要总结
To determine the safety and patient tolerance of UVAR Photopheresis System (extracorporeal photopheresis) in the Treatment of AIDS-Related Complex (ARC).
详细描述
Treatment involves the patient ingesting 8-methoxsalen (8-MOP) by mouth approximately two hours prior to each photopheresis session. The photopheresis instrument will separate the patient's white blood cells and some plasma from other blood components and return the majority of blood components to the patient. The separated white blood cells and plasma will be exposed to UVA (Ultraviolet A) light while outside the body. The UVA light photoactivates the 8-MOP drug which is now located in the DNA of the collected cells. After this exposure, the patients photoactivated white blood cells will be returned to the patient by venous access.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have the following:
- •Diagnosis of AIDS-related complex (ARC).
- •Veins that can provide adequate access.
- •Negative drug screen for drugs of abuse and zidovudine (AZT).
- •Be willing to adhere to the protocol and sign a patient informed consent prior to study entry.
- •Live within adequate commuting distance to the treatment center.
- •Not be on any other investigational drug/device.
- •Be 18 - 80 years old but minimum age requirements may be affected by state regulations or specific medical conditions.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Inability to tolerate extracorporeal volume loss during the leukocyte-enrichment phase.
- •Photosensitive disease, such as porphyria or systemic lupus erythematosus. Care must be taken in selecting patients who require drugs (either systemically or topically) during the course of the study with photosensitizing potential such as phenothiazines, tetracyclines, sulfonamides or chlorothiazide.
- •Renal insufficiency with creatinine > 3 mg/dl.
- •Symptoms of toxic effects (World Health Organization Criteria) resulting from previous therapy.
- •Severe emotional, behavioral or psychiatric problems that in the opinion of the investigator would result in poor compliance with the treatment regimen.
- •Idiosyncratic or hypersensitivity reactions to 8-MOP compounds.
- •History of or active Pneumocystis carinii pneumonia, other opportunistic infection or neoplasms (Kaposi's sarcoma), or wasting syndrome.
- •Active hepatitis.
- •Aphakia because of the significantly increased risk of retinal damage due to absence of lenses.
- •Concurrent Medication:
- •Zidovudine (AZT).
- •Photosensitizing drugs should not be administered prior to photopheresis treatment.
- •Other investigational drugs.
- •Concurrent Treatment:
- •Other treatment using an investigational device.
- •Patients with the following are excluded:
- •Inability to tolerate extracorporeal volume loss during the leukocyte-enrichment phase.
- •Photosensitive disease.
- •Symptoms of toxic effects (World Health Organization Criteria) resulting from previous therapy.
- •Severe emotional, behavioral or psychiatric problems that in the opinion of the investigator would result in poor compliance with the treatment regimen.
- •Idiosyncratic or hypersensitivity reactions to 8-MOP compounds.
- •Actively involved in drug abuse.
- •Aphakia because of the significantly increased risk of retinal damage due to absence of lenses.
- •Prior Medication:
- •Zidovudine (AZT).
- •Actively involved in drug abuse.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.Liver TransplantationImmunosuppressionNCT01824368Red de Terapia Celular10
已完成
不适用
Evaluation of a Photopneumatic System for the Treatment of AcneMild to Moderate AcneNCT01257555Solta Medical24
进行中（未招募）
3 期
Extracorporeal Photopheresis for Medicare Recipients of Lung AllograftsBronchiolitis Obliterans Syndrome (BOS)NCT02181257Washington University School of Medicine280
已完成
不适用
Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host DiseaseGraft-versus-host DiseaseNCT03124056Fundación para la Investigación del Hospital Clínico de Valencia62
终止
3 期
Safety Study of the VEGA UV-A System to Treat KeratoconusKeratoconusNCT01190306Topcon Medical Systems, Inc.127